Xbrane Biopharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	152.35	198.72	238.73	57.62	10.71
Revenue	152.35	198.72	238.73	57.62	10.71
Revenue Growth (YoY)	-23.33%	-16.76%	314.33%	438.03%	-
Cost of Revenue	62.81	18.23	203.34	-	-
Gross Profit	89.55	180.5	35.39	57.62	10.71
Selling, General & Admin	43.82	40.11	40.03	31.54	31.4
Research & Development	76.82	312.89	305.78	199.65	160.62
Other Operating Expenses	-2.85	30.54	-13.71	-20.91	-4.85
Operating Expenses	117.8	383.54	332.11	210.27	187.17
Operating Income	-28.25	-203.04	-296.72	-152.65	-176.46
Interest Expense	-15.69	-33.63	-18.5	-2.58	-2.64
Interest & Investment Income	-	0.5	2.41	0.3	-
Currency Exchange Gain (Loss)	-	-14.87	-9.15	-13.56	-4.13
Other Non Operating Income (Expenses)	0	-2.39	-0.06	-0.01	-0.01
Pretax Income	-43.93	-253.43	-322.03	-168.51	-183.23
Income Tax Expense	2.23	11.59	-	-	-
Earnings From Continuing Operations	-46.17	-265.02	-322.03	-168.51	-183.23
Earnings From Discontinued Operations	173.41	-1.2	-66.14	-4	-5.15
Net Income	127.24	-266.22	-388.17	-172.51	-188.38
Net Income to Common	127.24	-266.22	-388.17	-172.51	-188.38
Shares Outstanding (Basic)	12	10	0	0	0
Shares Outstanding (Diluted)	12	10	0	0	0
Shares Change (YoY)	23.72%	4184.97%	12.26%	8.38%	30.25%
EPS (Basic)	10.45	-27.06	-1690.32	-843.34	-998.04
EPS (Diluted)	10.45	-27.62	-1690.32	-843.34	-998.54
Free Cash Flow	-250.69	-134.23	-413.47	-205.53	-247.29
Free Cash Flow Per Share	-20.59	-13.64	-1800.48	-1004.76	-1310.16
Gross Margin	58.77%	90.83%	14.82%	100.00%	100.00%
Operating Margin	-18.54%	-102.17%	-124.29%	-264.94%	-1647.75%
Profit Margin	83.52%	-133.97%	-162.60%	-299.41%	-1759.04%
Free Cash Flow Margin	-164.55%	-67.55%	-173.20%	-356.72%	-2309.16%
EBITDA	-13.65	-193.86	-287.62	-145.21	-171.93
EBITDA Margin	-8.96%	-97.55%	-120.48%	-252.03%	-
D&A For EBITDA	14.6	9.18	9.1	7.44	4.53
EBIT	-28.25	-203.04	-296.72	-152.65	-176.46
EBIT Margin	-18.54%	-102.17%	-124.29%	-264.94%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.